Literature DB >> 11115467

Impact of BAL in the management of pneumonia with treatment failure: positivity of BAL culture under antibiotic therapy.

J C Pereira Gomes1, W L Pedreira, E M Araújo, F G Soriano, E M Negri, L Antonângelo, I Tadeu Velasco.   

Abstract

BACKGROUND: Pneumonia is responsible for 50% of antibiotics prescribed in ICUs. Treatment failure, ie, absence of improvement or clinical deterioration under antibiotic therapy, presents a dilemma to physicians. BAL is an invasive method validated for etiologic diagnosis in pneumonia. STUDY
OBJECTIVE: To evaluate in ICU patients the impact of BAL in the etiologic diagnosis, treatment, and outcome of pneumonia with treatment failure.
DESIGN: Prospective clinical study.
SETTING: Nonsurgical, medical ICU of a university hospital in Brazil. PATIENTS AND PARTICIPANTS: Sixty-two episodes of pneumonia treated for at least 72 h without clinical improvement in 53 patients hospitalized for diverse clinical emergencies. Mean duration of hospitalization was 14.2 days. Mean duration of previous antibiotic therapy was 11.4 days.
INTERVENTIONS: Bronchoscopy and BAL were performed in each episode. BAL fluid was cultivated for aerobic and anaerobic bacteria; the cutoff considered positive was 10(4) cfu/mL; 10(3) cfu/mL was also analyzed if under treatment. Pneumocystis carinii, fungi, Legionella spp, and Mycobacterium spp were also researched. MEASUREMENTS AND
RESULTS: Fifty-eight of 62 BAL were performed under antibiotics. The results showed positivity in 45 of 62 (72.6%); 42 of the 45 positive episodes (93.3%) had > 10(4) cfu/mL. The three cases with between 10(3) and 10(4) cfu/mL were considered positive and were treated according to BAL cultures. The main agents were Acinetobacter baumannii (37.1%), Pseudomonas aeruginosa (17.7%), and methicillin-resistant Staphylococcus aureus (MRSA; 16.1%); 46.7% of the episodes (21 of 45) were polymicrobial. BAL results directed a change of therapy in 34 episodes (54.8%). Overall mortality was 43.5%. There was no difference in mortality among positives, negatives, and patients who changed therapy guided by BAL culture.
CONCLUSIONS: (1) BAL fluid examination was positive in 45 of 62 episodes (72.6%), with 58 of 62 BAL performed under antibiotics. This suggests that BAL may be a sensitive diagnostic method for treatment failures of clinically diagnosed pneumonias, even if performed under antibiotics; (2) the main pathogens in our study were A baumannii, P aeruginosa, and MRSA, and approximately 45% of infections were polymicrobial; (3) BAL culture results directed a change of therapy in 75.6% of positive episodes (34 of 45) and in 54.8% of all episodes of treatment failure (34 of 62); and (4) there was no difference in mortality among positives, negatives, and patients who changed therapy guided by BAL culture.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11115467     DOI: 10.1378/chest.118.6.1739

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  11 in total

1.  Defining, treating and preventing hospital acquired pneumonia: European perspective.

Authors:  Antoni Torres; Santiago Ewig; Harmut Lode; Jean Carlet
Journal:  Intensive Care Med       Date:  2008-11-07       Impact factor: 17.440

2.  Staphylococcus aureus proteases degrade lung surfactant protein A potentially impairing innate immunity of the lung.

Authors:  Tomasz Kantyka; Krzysztof Pyrc; Milosz Gruca; Jan Smagur; Karolina Plaza; Krzysztof Guzik; Slawomir Zeglen; Marek Ochman; Jan Potempa
Journal:  J Innate Immun       Date:  2012-12-11       Impact factor: 7.349

3.  A low dimensional dynamical model of the initial pulmonary innate response to infection.

Authors:  Todd R Young; Richard Buckalew; Addison K May; Erik M Boczko
Journal:  Math Biosci       Date:  2012-01-04       Impact factor: 2.144

4.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

5.  Performance of a pneumolysin enzyme-linked immunosorbent assay for diagnosis of pneumococcal infections.

Authors:  María del Mar García-Suárez; María Dolores Cima-Cabal; Roberto Villaverde; Emma Espinosa; Miquel Falguera; Juan R de Los Toyos; Fernando Vázquez; Francisco J Méndez
Journal:  J Clin Microbiol       Date:  2007-08-29       Impact factor: 5.948

6.  Diagnostic value of bronchoalveolar lavage in leukemic and bone marrow transplant patients: the impact of antimicrobial therapy.

Authors:  Abraham Tareq Yacoub; Dani Thomas; Carol Yuan; Carolina Collazo; John Greene; Frank Walsh; David Solomon; Skai Schwartz; Arthur Andrews
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-01-01       Impact factor: 2.576

Review 7.  Current and Future Considerations for the Treatment of Hospital-Acquired Pneumonia.

Authors:  Philippe Montravers; Adela Harpan; Elise Guivarch
Journal:  Adv Ther       Date:  2016-02-09       Impact factor: 3.845

8.  Integron-Mediated Antibiotic Resistance in Acinetobacter baumannii Isolated from Intensive Care Unit Patients, Babol, North of Iran.

Authors:  Mitra Deylam Salehi; Elaheh Ferdosi-Shahandashti; Yosef Yahyapour; Soraya Khafri; Abazar Pournajaf; Ramazan Rajabnia
Journal:  Biomed Res Int       Date:  2017-07-19       Impact factor: 3.411

Review 9.  Diagnostic Evaluation of Pulmonary Abnormalities in Patients with Hematologic Malignancies and Hematopoietic Cell Transplantation.

Authors:  Bianca Harris; Alexander I Geyer
Journal:  Clin Chest Med       Date:  2017-06       Impact factor: 2.878

10.  Detection of Viruses by Multiplex Real-Time Polymerase Chain Reaction in Bronchoalveolar Lavage Fluid of Patients with Nonresponding Community-Acquired Pneumonia.

Authors:  Hao Zhang; Yinling Han; Zhangchu Jin; Yinghua Ying; Fen Lan; Huaqiong Huang; Shaobin Wang; Hongwei Zhou; Rong Zhang; Wen Hua; Huahao Shen; Wen Li; Fugui Yan
Journal:  Can Respir J       Date:  2020-11-25       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.